These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9126690)

  • 21. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Penetration of cefmenoxime into serum, gynecologic tissues, and heart valves.
    Daschner FD; Petersen EE; Frank U; Hornig D
    Am J Med; 1984 Dec; 77(6A):4-6. PubMed ID: 6097123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W; Pitkin DH; Nadler H
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A study on the penetration of imipenem/cilastatin sodium into the female genital tissues].
    Hongo M; Shimizu R; Sakae K; Kohchi T; Tada K; Tani M
    Jpn J Antibiot; 1986 May; 39(5):1389-400. PubMed ID: 3463785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya.
    Slaney L; Chubb H; Mohammed Z; Ronald A
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():183-6. PubMed ID: 2509415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.
    Wenzler E; Gotfried MH; Loutit JS; Durso S; Griffith DC; Dudley MN; Rodvold KA
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7232-9. PubMed ID: 26349830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
    Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
    Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery.
    Zhang Y; Zhang J; Chen Y; Yu J; Cao G; Wu X; Chen M; Wu J; Zhao X
    World Neurosurg; 2017 Feb; 98():525-531. PubMed ID: 27867128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group.
    García-Rodriguez JA; García Sánchez JE; Trujillano I; Sánchez de San Lorenzo A
    J Antimicrob Chemother; 1991 May; 27(5):599-606. PubMed ID: 1885418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
    Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
    Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of meropenem in patients with liver disease.
    Thyrum PT; Yeh C; Birmingham B; Lasseter K
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S184-90. PubMed ID: 9126692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE; Ashcraft D; Cambre K; Pierson CL; Jenkins SG; Rosenblatt JE
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antimicrobial activities of meropenem against clinically isolated strains. The result against strains isolated from blood and cerebrospinal fluid].
    Deguchi K; Koguchi M; Suzuki Y; Tanaka S; Fukayama S; Ishihara R; Oda S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1996 Apr; 49(4):377-85. PubMed ID: 8786628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.